More on new drug candidates against rheumatoi arthritis

There has been a comment to my blog at:

http://rheumatologe.blogspot.de/2012/07/fighting-rheumatoid-arthritis.html


Ville7 has written on 31st August 2012 12:58

Hallo Rheumatologe,
es ist Wahnsinn, wieviel Antikörper Medikamente derzeit gegen RA untersucht werden, man könnte die Liste fortführen mit

ACZ885 (Canakinumab), Target IL-1 beta
MDX-1100, Target CXCL10
MOR103, Target GM-CSF
KB-003, Target GM-CSF
Sirukumab, Target IL-6
BT061, Target CD4
Belimumab, Target BAFF
Veltuzumab, Target CD20
Golimumab, Target TNF-alpha
Mavrilimumab, Target GM-CSF

und wäre damit noch lange nicht vollständig.

Auf Clinicaltrials findet man unter dem Stichwort "rheumatoid arthritis" allein 231 Studien der Phasen 1 bis 3.


ACZ885 (Canakinumab), Target IL-1 beta, has been developed for the treatment of rheumatoid arthritis, but this indication has been abandoned. IL-1 beta isn’t a successful target in rheumatoid arthritis. Novartis tries desperately to find indications for its’ drug like gout as cryopyrin-associated periodic syndromes (CAPS) are orphan diseases.


MDX-1100, Target CXCL10, but doesn’t seem to be very effective: “The ACR50 and ACR70 response rates on day 85 did not differ between the groups.” http://www.ncbi.nlm.nih.gov/pubmed/22147649  The ACR20 response rate, however, was significantly higher among MDX-1100-treated patients. Lets wait for further results!


MOR103, Target GM-CSF, there is some interesting data, but only published by MorphoSys: http://www.morphosys.com/pressrelease/morphosyss-mor103-antibody-demonstrates-excellent-safety-and-efficacy-rheumatoid-arthritis-patients . Lets wait for the discussions at the ACR2012 next month!


KB-003, Target GM-CSF, “The study was terminated upon completion of safety run-in due to program refocus.” http://clinicaltrials.gov/ct2/show/results/NCT00995449  


Sirukumab, Target IL-6, please look at: http://rheumatologe.blogspot.de/2012/07/sirukumab-at-eular-2012.html (it’s a me too drug).


BT061, Target CD4, “Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)”, Estimated Study Completion Date: December 2013. http://clinicaltrials.gov/ct2/show/NCT01481493


Belimumab, Target BAFF, “Belimumab has also undergone phase II clinical trials for rheumatoid arthritis.[6] Preliminary results in November 2005 were encouraging,[7] but no clinical trials are ongoing as of April 2012” - http://en.wikipedia.org/wiki/Belimumab.


Veltuzumab, Target CD20, VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis – the study is ongoing. Let’s wait for results! And please check: http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html  

Golimumab, Target TNF-alpha, is already on the market!

Mavrilimumab, Target GM-CSF – please check: http://rheumatologe.blogspot.de/2012/07/mavrilimumab-at-eular-2012.html  


All in all I like the efforts for new drugs, but we have to wait for stable results!


Please check also: http://rheumatologe.blogspot.de/2012/05/some-small-molecules-in-pipeline.html